Study of anifrolumab for fatigue in lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests whether a medicine called anifrolumab can help reduce severe tiredness (fatigue) in people with lupus. It is for adults whose lupus is mostly under control but who still feel very tired.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old.
- You have been diagnosed with lupus (SLE) by a doctor.
- You have had significant fatigue (rated 6 or higher on a 0-10 scale) for more than 3 months.
- Your lupus is in a low disease activity state, meaning it is mostly quiet.
- You are not currently taking other biologic medicines for lupus.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control during the study and for 12 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
This study tests an experimental drug called anifrolumab, which is given as an injection or infusion, to see how it works in people with active lupus. It may help reduce lupus symptoms by targeting the immune system.
This study tracks how well anifrolumab works and how safe it is for people with active lupus. It's a real-world look at the drug's effects, so no additional treatments or tests are required beyond what your doctor already prescribes.
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
This study tests whether anifrolumab, a drug that targets the immune system, can improve markers of blood vessel health in people with lupus. It may help reduce the risk of heart problems associated with lupus.
This study tests anifrolumab, a new injection medicine that may help control systemic lupus erythematosus (SLE) in children and teens. Researchers will measure how the body processes the medicine and whether it helps reduce lupus activity while monitoring for side effects.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.